PH
Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
$9.50 +5.67% (+$0.51)
1M +11.11%
Market Cap $732.2M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$13.21
39.1% upside
Trenutna cena
$9.5
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica PHAT trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
3/9Valuation
57 /100
Fair P/S 3.05x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 82.92%
Net margin 41.34%
Op. margin 16.96%
Quality
13 /100
Poor ROIC 23.36%
ROA 30.29%
Asset turnover 0.73x
Debt
41 /100
Moderate Current ratio 1.92x
Int. coverage -0.56x
Debt/Equity N/A
Stability
49 /100
Moderate Beta 0.51x
EPS volatility 41.69%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o PHAT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Steven L. Basta
Employees
371
Headquarters
Florham Park
Prihajajoči dogodki
29 OKT.
Earnings
Upcoming earnings report